Rexahn Pharmaceuticals Inc (REXN) Com Stk USD0.0001
Rexahn Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery, development and commercialization of treatments for cancer. The Company's pipeline features two clinical stage oncology product candidates and additional compounds in preclinical development. Its pipeline includes RX-3117, RX-5902 and RX-0301. RX-3117 is an investigational oral small molecule nucleoside compound. RX-5902 is a potential small molecule modulator of the Wnt/beta-catenin pathway, which plays a role in cancer cell proliferation and tumor growth. RX-5902 modulates the pathway through inhibition of phosphorylated p68, a protein that helps to transport beta-catenin from the cytoplasm into the cell nucleus. RX-0301 is being developed as a nano-liposomal formulation of RX-0201, an antisense oligonucleotide compound that is complementary to mRNA coding for Akt-1.
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.